People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spruce Biosciences, Inc. | — | Biotechnology | Series C | $191.6M | $274.5M | 2023 |
| Affymax Inc | — | Biotechnology | Series C | $42.0M | $1.7B | 2009 |
Daniel Spiegelman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Spiegelman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Michael Grey | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Niall O'Donnell | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| Ted W. Love | 1 | 5 |
| Arlene Morris | 1 | 5 |
| Richard King | 1 | 3 |
| Keith Leonard | 1 | 3 |
| Bali Muralidhar | 1 | 3 |
| Kathleen LaPorte | 1 | 2 |
| JONAS HANSSON | 1 | 2 |
| Steven Love | 1 | 2 |
| R. Lee Douglas | 1 | 2 |
| Robert Venteicher | 1 | 1 |
| Kirk Ways | 1 | 1 |
| Javier Szwarcberg | 1 | 1 |
| Simpson Camilla | 1 | 1 |
| Percival Barretto-Ko | 1 | 1 |
| Samir Gharib | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.